Messori A. Approval of pembrolizumab for first-line treatment of microsatellite instability-high/mismatch repair deficient colorectal cancer: estimation of incremental benefit based on restricted mean survival time. Eur J Gastroenterol Hepatol 2021;33:763.
PMID: 33787545